Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:
   

China Approves CanSino COVID-19 Vaccine for Military

publication date: Jun 29, 2020
 | 
author/source: Richard Daverman, PhD

The COVID-19 vaccine developed by CanSino Biologics (HK 6185) of Tianjin was approved for use by military personnel in China. So far, the company has completed only a Phase I/IIa trial of the candidate. CanSino has not yet started a Phase III test, though it has published positive data from the Phase I/IIa trial of the vaccine showing that it was safe with preliminary signs of efficacy. The vaccine is an adeno-associated virus serotype 5 (AAV5) vector encoding the SARS-CoV-2 spike protein. CanSino is partnering development of the vaccine with China's Academy of Military Medical Sciences.

The other China vaccines that have advanced past Phase I trials are all inactivated vaccines. CanSino's candidate, known as Ad5-nCoV, is a more modern technology. The company and AMMS previously collaborated on an Ebola vaccine with an adeno-associated virus vector that was approved for use after the Ebola epidemic had run its course. It is used to treat people who embark on missions in the Democratic Republic of Congo.

China’s Central Military Commission approved the use of the vaccine by the military on June 25 for a period of one year, CanSino said in a filing to the Hong Kong exchange.

“The Ad5-nCoV is currently limited to military use only and its use cannot be expanded to a broader vaccination range without the approval of the Logistics Support Department,” CanSino said, referring to the Central Military Commission department which approved the military use of the vaccine.

China's other vaccine candidates that have started Phase II trials have been made available to employees at China state-owned firms who are traveling overseas.

See our other articles on CanSino.

Disclosure: none.

 



 

Share this with colleagues:

 

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes


Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China